Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios as markers of erythropoietin resistance in chronic haemodialysis patients: a multicentre cross-sectional study

被引:11
|
作者
Valga, Francisco [1 ,2 ]
Monzon, Tania [1 ,2 ]
Henriquez, Fernando [1 ,2 ,3 ,4 ]
Santana-del-Pino, Angelo [5 ]
Anton-Perez, Gloria [1 ,2 ,3 ,4 ]
机构
[1] Ctr Dialisis Avericum Negrin, Las Palmas Gran Canaria, Islas Canarias, Spain
[2] Ctr Dialisis Avericum Guia, Santa Maria De Guia, Islas Canarias, Spain
[3] Ctr Dialisis Avericum Telde, Las Palmas Gran Canaria, Islas Canarias, Spain
[4] Ctr Dialisis Avericum Lanzarote, Arrecife, Islas Canarias, Spain
[5] Univ Las Palmas Gran Canaria, Dept Matemat, Las Palmas Gran Canaria, Islas Canarias, Spain
来源
NEFROLOGIA | 2020年 / 40卷 / 03期
关键词
Chronic haemodialysis; Erythropoietin resistance; Platelet-lymphocyte ratio; Neutrophil-lymphocyte ratio; ALL-CAUSE MORTALITY; STIMULATING AGENT; KIDNEY-TRANSPLANT; PROGNOSTIC-FACTOR; ANEMIA; HEMOGLOBIN; DISEASE; INDEX;
D O I
10.1016/j.nefro.2019.09.007
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The platelet-to-lymphocyte (PLR) and neutrophil-to-lymphocyte (NLR) ratios are emerging markers of inflammation. Erythropoietin resistance is associated with increased morbidity and mortality in patients with chronic kidney disease and is influenced by inflammation, among other factors. Therefore, it would be reasonable to expect a relationship between these markers and erythropoietin resistance. Methods: Multicentre cross-sectional study. The records of the haemodialysis sessions of 534 patients belonging to four of our dialysis centres were studied. 137 patients were excluded, so the final number of patients studied was 397. NLR, PLR and the erythropoietin resistance index (ERI) were calculated. Results: The ERI was divided into quartiles and compared with the mean NLR and PLR of the four groups, with these differences being statistically significant (p = 0.00058). In the regression analysis, the NLR value was able to predict ERI significantly (p < 0.0001) (R-2 = 0.029). The PLR value also predicted ERI significantly (p < 0.0001) (R-2 = 0.103). The ability of PLR to predict erythropoietin resistance was measured with the area under the ROC curve (AUC = 0.681) (95% CI, 0.541-0.821). A PLR cut-off point of 125.5 would result in a sensitivity of 80.95% and 42.82% specificity. Conclusions: Both PLR and NLR could be considered acceptable markers of erythropoietin resistance. The PLR was a better predictor for the ERI than the NLR. (C) 2019 Sociedad Espanola de Nefrologia. Published by Elsevier Espana, S.L.U.
引用
收藏
页码:320 / 327
页数:8
相关论文
共 50 条
  • [31] Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios in Crohn's disease: The controversy remains
    Jaoude, Joseph Bou
    Bakouny, Ziad
    Hallit, Rachel
    Honein, Khalil
    Ghorra, Claude
    El Rassy, Elie
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2018, 42 (01) : E16 - E18
  • [32] Diagnostic value of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in adnexal torsion cases
    Kinay, Tugba
    Akgul, Mehmet A.
    Kiykac Altinbas, Sadiman
    Tapisiz, Omer L.
    Kayikcioglu, Fulya
    Moraloglu Tekin, Ozlem
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2021, 47 (05) : 1846 - 1853
  • [33] The combination of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as a novel predictor of intravenous immunoglobulin resistance in patients with Kawasaki disease: a multicenter study
    Takashi Kanai
    Seiichiro Takeshita
    Yoichi Kawamura
    Keiji Kinoshita
    Keigo Nakatani
    Satoru Iwashima
    Yuji Takizawa
    Keiichi Hirono
    Kazuetsu Mori
    Yusuke Yoshida
    Shigeaki Nonoyama
    Heart and Vessels, 2020, 35 : 1463 - 1472
  • [34] Evaluation of frailty and neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios relationship in elderly people
    Asik, Zeynep
    Ozen, Mehmet
    NAGOYA JOURNAL OF MEDICAL SCIENCE, 2022, 84 (01): : 101 - 110
  • [35] Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer
    Al Jarroudi, Ouissam
    El Bairi, Khalid
    Abda, Naima
    Zaimi, Adil
    Jaouani, Laila
    Chibani, Hind
    Afqir, Said
    BIOMARKERS IN MEDICINE, 2021, 15 (14) : 1289 - 1298
  • [36] Association of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios with coronary artery disease severity
    Ramezani, Javad
    Kalat, Hamidreza Bagherian
    Hashemian, Amir Masoud
    Mehramiz, Neema John
    Foroughian, Mandi
    MEDICAL SCIENCE, 2019, 23 (96) : 211 - 216
  • [37] Neutrophil-To-Lymphocyte and Platelet-To-Lymphocyte Ratios as Prognostic Biomarkers in Early NSCLC Patients Treated with SABR
    Mckay, Stephen
    Moore, Karen
    Macphee, Jennifer
    Hicks, Jonathan
    Lumsden, Graeme
    Maclaren, Vivienne
    Mcloone, Philip
    Harrow, Stephen
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S634 - S635
  • [38] Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and prognosis after aneurysmal subarachnoid hemorrhage: a cohort study
    de Oliveira, Adilson Jose Manuel
    Rabelo, Nicollas Nunes
    Telles, Joao Paulo Mota
    Solla, Davi Jorge Fontoura
    da Silva Coelho, Antonio Carlos Samaia
    Barbosa, Guilherme Bitencourt
    Barbato, Natalia Camargo
    Yoshikawa, Marcia Harumy
    Teixeira, Manoel Jacobsen
    Figueiredo, Eberval Gadelha
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2023, 81 (06) : 515 - 523
  • [39] Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Predicts the Disease Activity in Patients with Paediatric Systemic Lupus Erythematosus: An Observational Cross-Sectional Study
    Nath, Paromita
    Raychaudhuri, Dibyendu
    Kisku, Himadri Sekhar
    Bankura, Biswabandhu
    Datta, Kalpana
    Nandy, Manab
    Mondal, Rakesh
    MEDITERRANEAN JOURNAL OF RHEUMATOLOGY, 2024, 35 (04):
  • [40] Association of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio with Diabetic Kidney Disease in Chinese Patients with Type 2 Diabetes: A Cross-Sectional Study
    Li, Lan
    Shen, Qing
    Rao, Sijie
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2022, 18 : 1157 - 1166